Sure. Let me build it up from the core problem.

## The Problem MR Is Solving

Suppose you want to know whether high LDL cholesterol actually *causes* heart disease, or whether they just tend to occur together because of some third factor — maybe people who eat poorly have both high LDL and heart disease, and the diet is the real culprit.

With observational data, this is really hard to untangle. You can adjust for confounders, but you can never be sure you got them all. This is the fundamental problem you know well from epidemiology.

## The Key Insight

Your DNA is assigned at conception, randomly, before you develop any diseases or lifestyle habits. It doesn't change based on what you eat, whether you're stressed, or what your socioeconomic status is. So if a particular genetic variant reliably raises your LDL cholesterol — just mechanically, because of how your biology works — then people who inherited that variant will tend to have higher LDL through no fault of their lifestyle.

That randomness is the key. It's almost like nature ran a randomized controlled trial at the moment of conception — some people got the "higher LDL" variant, some didn't, and it was essentially random which group you ended up in.

## The Analogy to a Clinical Trial

In a regular RCT, you randomly assign people to take a cholesterol-lowering drug or a placebo. Random assignment means the two groups are comparable on everything except the drug, so any difference in outcomes must be caused by the drug.

MR uses the genetic variant the same way a trial uses randomization. People who inherited the LDL-raising variant are like the "high LDL" treatment group. People who didn't are like the control group. Because assignment was random at conception, the groups should be comparable on everything else. So if the high-variant group has more heart disease, that's strong evidence that LDL actually causes it — not just correlates with it.

The genetic variant is called the **instrument** — it's the thing doing the random assignment.

## Why This Matters for Drug Discovery

Here's where it gets directly relevant to what you want to do. If you have a genetic variant that mimics what a drug does — say, a variant that naturally lowers a protein your drug would inhibit — you can use MR to ask "what happens to people who naturally have less of this protein their whole lives?" That tells you something about what the drug would do, *before you ever make the drug.*

This is called **target validation using human genetic evidence**, and it's one of the most valuable things pharma does with this method. Drugs that have human genetic evidence supporting their target are substantially more likely to succeed in clinical trials. The famous statistic cited in the field is roughly twice the success rate.

## The Three Requirements for a Valid Instrument

For a genetic variant to work as an instrument it needs to satisfy three conditions, which are worth knowing because they're where the method can go wrong:

1. **It must actually affect the exposure** — the variant genuinely changes your LDL level, not just correlate with it weakly
2. **It must only affect the outcome through the exposure** — the variant shouldn't raise heart disease risk through some completely separate biological pathway unrelated to LDL
3. **It must be independent of confounders** — because it's inherited randomly, it shouldn't correlate with diet, lifestyle, socioeconomic status, etc.

The second assumption is the one that's hardest to verify and the source of most criticism of MR studies. Many genetic variants affect multiple traits (this is called pleiotropy), so they might influence the outcome through pathways you didn't intend. A lot of the methodological machinery in MR — MR-Egger regression, weighted median estimators — exists specifically to detect and correct for this.

## How It Connects to OMOP

In a typical MR study you need two things for each person: their genetic variant status, and their outcome (disease diagnosis, lab value, etc.). OMOP CDM is very good at providing the second part — structured, standardized clinical data. The gap is linking it to genotype data. When that linkage exists, you can run MR at scale across large populations. That's the infrastructure problem your package would solve.

Does that make the method feel grounded enough to work with, or would it help to walk through a concrete example end to end?
